BioStock: CMO gives insight on new BioInvent collaboration

Having achieved a strong shareholder base, several important partnerships and a very successful capital raise last year, biotech company BioInvent has received yet another quality stamp. This one comes in the form of a collaboration agreement with the Leukemia & Lymphoma Society - whose blood cancer acceleration programme invests 3 MUSD in the company through a directed new issue. Going forward, BioInvent will get access to important knowledge and guidance from the patient organisation. BioStock contacted CMO Andres McAllister to get his comment.

Read the article about BioInvent at biostock.se:

https://www.biostock.se/en/2023/01/cmo-gives-insight-on-new-bioinvent-collaboration/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/